Research Summary

Dr. Chloe E. Atreya specializes in gastrointestinal cancer, particularly colorectal cancer, at the UCSF Helen Diller Comprehensive Cancer Center. She also co-directs the Integrative Onolcogy Program and Research Hub. Her research focuses on the interplay of tumor genetics and response to therapies for colorectal cancer, with the goal of improving patient outcomes and quality of life by personalizing treatment.

Research Funding

  • January 1, 2022 - December 21, 2026 - Understanding Intrinsic Resistance to Direct KRAS Inhibition In colorectal Cancers , Co-Investigator . Sponsor: NIH-NCI, Sponsor Award ID: R37CA266549
  • September 1, 2020 - August 1, 2025 - Optimization of a remote intervention to improve nutrition and physical activity in colorectal cancer survivors , Co-Investigator . Sponsor: NIH/NCI, Sponsor Award ID: R01CA248774
  • June 1, 2019 - May 31, 2024 - Kinome-guided Targeting of Cooperative Dependencies in BRAF and KRAS Mutated Colorectal Cancer , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA229447
  • June 21, 2018 - May 31, 2021 - (PQ10) Harnessing the human gut microbiome to predict chemotherapy outcomes , Co-Principal Investigator . Sponsor: NIH, Sponsor Award ID: R21CA227232

Education

Princeton University,  Princeton NJ, BA, 05/98, Molecular Biology,  Certificate in Visual Art
Yale University,  New Haven,  CT, PhD, 05/04, Pharmacology
Yale University,  New Haven,  CT, MD, 05/05, Medicine
University of Washington,  Seattle,  WA, 06/08, Internal Medicine,  internship and residency
University of California,  San Francisco, 06/10, Medical Oncology,  fellowship
University of California, San Francisco, 06/14, Certificate, Advanced Training in Clinical Research
University of California, San Francisco, 2018-2019, Clinical Fellowship in Integrative Medicine

Honors & Awards

  • University of Michigan Human Genome Center, Ann Arbor, MI
    1993, 92 Howard Hughes Summer Internships with Dr. Francis Collins
  • Princeton University, Princeton, NJ
    1998 Bachelor of Arts, Molecular Biology, High Honors
    1998 Phi Beta Kappa
    1998 Sigma Xi
    1997 Lucas Graphics Prize for the best graphic image by a Princeton student
  • Yale University School of Medicine, New Haven, CT
    2005 MD-PhD Alumni Award
    2005 Janet M. Glasgow Memorial Achievement Citation, presented by the American Medical Women's Association to women who graduate at the top of their medical school class
  • 2011
    American Cancer Society Postdoctoral Fellowship 11-183-01-TBG
  • 2011
    Conquer Cancer Foundation of the American Society of Clinical Oncology Young Investigator Award
  • 2012
    UCSF Resource Allocation Program Spring 2012 Core Exploratory Award
  • 2012
    Alliance for Clinical Trials in Oncology Foundation Investigator Award
  • 2012
    Pilot Research Award for Junior Investigators, Mt. Zion Health Fund, Gump Cancer Fund from the Resource Evaluation and Allocation Committee, and HDFCCC
  • 2014
    The Ernest H. Rosenbaum MD Commitment to Patient Care Award, UCSF Symptom Management Service
  • 2017
    The Marcus Program in Precision Medicine Innovation Seeding Bold Ideas Award
  • 2017
    Inside Out Accelerator Award, UCSF Clinical Innovation Center

Selected Publications

  1. Piawah S, Walker EJ, Van Blarigan EL, Atreya CE. The Gut Microbiome in Colorectal Cancer. Hematol Oncol Clin North Am. 2022 06; 36(3):491-506.  View on PubMed
  2. Chan H, Van Loon K, Kenfield SA, Chan JM, Mitchell E, Zhang L, Paciorek A, Joseph G, Laffan A, Atreya C, Fukuoka Y, Miaskowski C, Meyerhardt JA, Venook AP, Van Blarigan EL. Quality of life of colorectal cancer survivors participating in a pilot randomized controlled trial of physical activity trackers and daily text messages. Support Care Cancer. 2022 May; 30(5):4557-4564.  View on PubMed
  3. Van Blarigan EL, Dhruva A, Atreya CE, Kenfield SA, Chan JM, Milloy A, Kim I, Steiding P, Laffan A, Zhang L, Piawah S, Fukuoka Y, Miaskowski C, Hecht FM, Kim MO, Venook AP, Van Loon K. Feasibility and Acceptability of a Physical Activity Tracker and Text Messages to Promote Physical Activity During Chemotherapy for Colorectal Cancer: Pilot Randomized Controlled Trial (Smart Pace II). JMIR Cancer. 2022 Jan 11; 8(1):e31576.  View on PubMed
  4. Burns S, Vella M, Paciorek A, Zhang L, Atreya CE, Feng M, Kelley RK, Tempero MA, Van Loon K, Ko AH. Characteristics and Growth Rate of Lung Metastases in Patients With Primary Gastrointestinal Malignancies and Lung-dominant Metastatic Disease: A Retrospective Cohort Analysis. Am J Clin Oncol. 2022 01 01; 45(1):22-27.  View on PubMed
  5. Combes AJ, Samad B, Tsui J, Chew NW, Yan P, Reeder GC, Kushnoor D, Shen A, Davidson B, Barczak AJ, Adkisson M, Edwards A, Naser M, Barry KC, Courau T, Hammoudi T, Argüello RJ, Rao AA, Olshen AB, Immunoprofiler Consortium, Cai C, Zhan J, Davis KC, Kelley RK, Chapman JS, Atreya CE, Patel A, Daud AI, Ha P, Diaz AA, Kratz JR, Collisson EA, Fragiadakis GK, Erle DJ, Boissonnas A, Asthana S, Chan V, Krummel MF. Discovering dominant tumor immune archetypes in a pan-cancer census. Cell. 2022 01 06; 185(1):184-203.e19.  View on PubMed
  6. Dragomanovich HM, Dhruva A, Ekman E, Schoenbeck KL, Kubo A, Van Blarigan EL, Borno HT, Esquivel M, Chee B, Campanella M, Philip EJ, Rettger JP, Rosenthal B, Van Loon K, Venook AP, Boscardin C, Moran P, Hecht FM, Atreya CE. Being Present 2.0: Online Mindfulness-Based Program for Metastatic Gastrointestinal Cancer Patients and Caregivers. Glob Adv Health Med. 2021; 10:21649561211044693.  View on PubMed
  7. Keenan BP, VAN Loon K, Khilnani AD, Fidelman N, Behr SC, Atreya CE, Oh DY. Molecular and Radiological Features of Microsatellite Stable Colorectal Cancer Cases With Dramatic Responses to Immunotherapy. Anticancer Res. 2021 Jun; 41(6):2985-2992.  View on PubMed
  8. Kopetz S, Guthrie KA, Morris VK, Lenz HJ, Magliocco AM, Maru D, Yan Y, Lanman R, Manyam G, Hong DS, Sorokin A, Atreya CE, Diaz LA, Allegra C, Raghav KP, Wang SE, Lieu CH, McDonough SL, Philip PA, Hochster HS. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). J Clin Oncol. 2021 02 01; 39(4):285-294.  View on PubMed
  9. Atreya CE, Collisson EA, Park M, Grenert JP, Behr SC, Gonzalez A, Chou J, Maisel S, Friedlander TW, Freise CE, Shoji J, Semrad TJ, Van Ziffle J, Chin-Hong P. Molecular Insights in Transmission of Cancer From an Organ Donor to Four Transplant Recipients. J Natl Compr Canc Netw. 2020 11; 18(11):1446-1452.  View on PubMed
  10. Van Blarigan EL, Zhang S, Ou FS, Venlo A, Ng K, Atreya C, Van Loon K, Niedzwiecki D, Giovannucci E, Wolfe EG, Lenz HJ, Innocenti F, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA. Association of Diet Quality With Survival Among People With Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial. JAMA Netw Open. 2020 10 01; 3(10):e2023500.  View on PubMed
  11. Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB, Boland P, Chung K, Copur MS, Corcoran RB, Deming DA, Dwyer A, Diehn M, Eng C, George TJ, Gollub MJ, Goodwin RA, Hamilton SR, Hechtman JF, Hochster H, Hong TS, Innocenti F, Iqbal A, Jacobs SA, Kennecke HF, Lee JJ, Lieu CH, Lenz HJ, Lindwasser OW, Montagut C, Odisio B, Ou FS, Porter L, Raghav K, Schrag D, Scott AJ, Shi Q, Strickler JH, Venook A, Yaeger R, Yothers G, You YN, Zell JA, Kopetz S. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol. 2020 12; 17(12):757-770.  View on PubMed
  12. Susko M, Wang CJ, Lazar AA, Kim S, Laffan A, Feng M, Ko A, Venook AP, Atreya CE, Van Loon K, Anwar M. Factors Impacting Differential Outcomes in the Definitive Radiation Treatment of Anal Cancer Between HIV-Positive and HIV-Negative Patients. Oncologist. 2020 09; 25(9):772-779.  View on PubMed
  13. Atreya CE, Turnbaugh PJ. Probing the tumor micro(b)environment. Science. 2020 05 29; 368(6494):938-939.  View on PubMed
  14. Bischoff KE, Zapata C, Sedki S, Ursem C, O'Riordan DL, England AE, Thompson N, Alfaro A, Rabow MW, Atreya CE. Embedded palliative care for patients with metastatic colorectal cancer: a mixed-methods pilot study. Support Care Cancer. 2020 Dec; 28(12):5995-6010.  View on PubMed
  15. Middleton G, Yang Y, Campbell CD, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, De Vos F, Van Cutsem E, Millholland JM, Brase JC, Rangwala F, Gasal E, Corcoran RB. BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer. Clin Cancer Res. 2020 06 01; 26(11):2466-2476.  View on PubMed
  16. Ursem C, Zhou M, Paciorek A, Atreya CE, Ko AH, Venook A, Zhang L, Van Loon K. Clinicopathologic Characteristics and Impact of Oophorectomy for Ovarian Metastases from Colorectal Cancer. Oncologist. 2020 07; 25(7):564-571.  View on PubMed
  17. Gonzalez A, Walker EJ, Van Loon K, Cinar P, Atreya CE. Postoperative Exacerbation of Oxaliplatin-induced Neurotoxicity in Gastrointestinal Cancers: A Case Series. Anticancer Res. 2020 02; 40(2):865-871.  View on PubMed
  18. Van Blarigan EL, Kenfield SA, Chan JM, Van Loon K, Paciorek A, Zhang L, Chan H, Savoie MB, Bocobo AG, Liu VN, Wong LX, Laffan A, Atreya CE, Miaskowski C, Fukuoka Y, Meyerhardt JA, Venook AP. Feasibility and Acceptability of a Web-Based Dietary Intervention with Text Messages for Colorectal Cancer: A Randomized Pilot Trial. Cancer Epidemiol Biomarkers Prev. 2020 04; 29(4):752-760.  View on PubMed
  19. Savoie MB, Paciorek A, Zhang L, Van Blarigan EL, Sommovilla N, Abrams D, Atreya CE, Bergsland EK, Chern H, Kelley RK, Ko A, Laffan A, Sarin A, Varma MG, Venook AP, Van Loon K. Vitamin D Levels in Patients with Colorectal Cancer Before and After Treatment Initiation. J Gastrointest Cancer. 2019 Dec; 50(4):769-779.  View on PubMed
  20. Le DT, Kim TW, Van Cutsem E, Geva R, Jäger D, Hara H, Burge M, O'Neil B, Kavan P, Yoshino T, Guimbaud R, Taniguchi H, Elez E, Al-Batran SE, Boland PM, Crocenzi T, Atreya CE, Cui Y, Dai T, Marinello P, Diaz LA, André T. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. J Clin Oncol. 2020 01 01; 38(1):11-19.  View on PubMed

Go to UCSF Profiles, powered by CTSI